Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

ferbi s.r.l., viale 1o maggio, contrada ripoli, 64023 mosciano sant’angelo (te) (italija). - cipermetrinas - veikliosios medžiagos cas nr.: 52315-07-8, eb nr.: 257-842-9, veikliosios medžiagos pavadinimas: cipermetrinas, koncentracija: 0.25% , veiklioji - insekticidai, akaricidai ir kitų nariuotakojų kontrolės produktai

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

ferbi s.r.l., viale 1o maggio, contrada ripoli, 64023 mosciano sant’angelo (te) (italija). - permetrinas; permetrinas; permetrinas - veikliosios medžiagos cas nr.: 52645-53-1, eb nr.: 258-067-9, veikliosios medžiagos pavadinimas: permetrinas, koncentracija: 9.5% , veiklioji; veikliosios medžiagos cas nr.: 52645-53-1, eb nr.: 258-067-9, veikliosios medžiagos pavadinimas: permetrinas, koncentracija: 9.5% , veiklioji; veikliosios medžiagos cas nr.: 52645-53-1, eb nr.: 258-067-9, veikliosios medžiagos pavadinimas: permetrinas, koncentracija: 9.5% , veiklioji - insekticidai, akaricidai ir kitų nariuotakojų kontrolės produktai

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - daugybinė mieloma - imunosupresantai - imnovid kartu su bortezomib ir dexamethasone yra nurodyta gydymas suaugusiems pacientams, sergantiems daugybine mieloma, kurie gavo bent vieną prieš gydymo režimą, įskaitant lenalidomide. imnovid kartu su deksametazonu yra skirtas gydyti suaugusiems pacientams, sergantiems recidyvuojančia ir ugniai atsparios daugybine mieloma kurie gavo ne mažiau kaip du gydymo režimai, įskaitant lenalidomide ir bortezomibo, ir parodė ligos progresavimo po paskutinio gydymo.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - lenalidomidas - multiple myeloma; lymphoma, mantle-cell; myelodysplastic syndromes - imunosupresantai - kelis myelomarevlimid kaip monotherapy yra nurodyta techninės priežiūros gydymas suaugusiems pacientams su naujai diagnozuota, daugybine mieloma, kurie buvo autologinių kamieninių ląstelių transplantacijos. revlimid kaip terapijos derinys su dexamethasone, ar bortezomib ir dexamethasone, ar melphalan ir prednizolonas (žr. skyrių 4. 2) yra nurodytos gydyti suaugusiems pacientams su anksčiau negydytų mieloma, kurie nėra tinkami persodinti. revlimid kartu su dexamethasone nurodomas gydymo mieloma suaugusiųjų pacientų, kurie gavo bent vieną prieš terapija. mielodisplazinio syndromesrevlimid kaip monotherapy fluorouracilu ir folino suaugusių pacientų su perpylimo priklauso nuo anemija, dėl žemos ar vidutinės 1-rizikos mielodisplazinio susiję sindromai su atskiru išbraukta 5q cytogenetic anomalija, kai kitos gydymo galimybės yra nepakankamos arba netinkamos. mantijos ląstelių lymphomarevlimid kaip monotherapy fluorouracilu ir folino suaugusių pacientų su atsinaujino arba ugniai atsparios mantijos ląstelių limfoma. follicular lymphomarevlimid kartu su rituximab (anti-cd20 antikūnų) fluorouracilu ir folino suaugusių pacientų, kurių anksčiau gydytų follicular limfoma (lygis 1 – 3a).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - efavirenzas - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - sustiva yra vartojamas kartu su priešvirusiniais vaistais, sergantiems žmogaus imunodeficito virusu-1 (Živ-1) infekuotais suaugusiais, paaugliais ir trejų metų amžiaus vaikais. sustiva nebuvo tinkamai tirti pacientai, sergantys progresavusia Živ liga, t. y. pacientams, kurių cd4 skaičius < 50 ląstelių/mm3, ar po nesėkmės proteazė-inhibitorius (pi)-kurių sudėtyje režimų. nors kryžminis atsparumas efavirenz su pis nebuvo patvirtinti, yra šiuo metu nepakanka duomenų apie veiksmingumo vėliau naudoti pi pagrįstos terapijos derinys, kai sugenda režimų, kurių sudėtyje yra sustiva.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antinavikiniai vaistai - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 ir 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumabas - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - antinavikiniai vaistai - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

bristol-myers squibb gyogyszerkereskedelmi kft. - cefepimas - milteliai injekciniam ar infuziniam tirpalui - 1 g - cefepime

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

zoetis belgium sa - sevofluranas - anestetikai, bendrojo - dogs; cats - Šunims ir katėms sukelti ir išlaikyti anesteziją.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

chanelle pharmaceuticals manufacturing limited - sevofluranas - anestetikai, bendrojo - dogs; cats - anestezijos indukcijai ir priežiūrai.